Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia


Khayat C. D. , El Khorassani M., Aytac S., Harroche A., Dahmane A., Pujol S., ...Daha Fazla

THROMBOSIS AND HAEMOSTASIS, cilt.120, ss.957-967, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 120 Konu: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1055/s-0040-1710015
  • Dergi Adı: THROMBOSIS AND HAEMOSTASIS
  • Sayfa Sayıları: ss.957-967

Özet

Objective To date, the use of a fibrinogen concentrate (FC) administered in children with inherited fibrinogen deficiency is poorly documented. Treatment modalities may differ from those of adults. The aim of this study was to investigate the pharmacokinetics (PK), efficacy (bleeding/surgery) and safety of a triple-secured FC (FibCLOT, LFB, France) in young patients aged of 12 years or less.